Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

NCT04950075 is registered in ClinicalTrials.gov with Inhibrx Biosciences, Inc as lead sponsor.

NCT NCT04950075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04950075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Lead sponsor
Inhibrx Biosciences, Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 23, 2021
Completion date
December 31, 2026
Enrollment
206 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

conventional chondrosarcoma